Ionis Pharmaceuticals — Apr 29, 2026 release

    Full Year 2026 Guidance Previous Guidance New Guidance Total Revenue $800-825 million $875-900 million TRYNGOLZA   product sales, net NA $100-110 million DAWNZERA   product sales, net NA $110-120 million Operating loss on a non-GAAP basis $500-550 million $425-475 million Cash, cash equivalents and short-term investments >$1.6 billion >$1.6 billion Webcast and Other Updates Management will host a conference call and webcast to discuss Ionis’ first quarter 2026 results at 8:30 a.m. Eastern time on Wednesday, April 29, 2026. Interested parties may access the webcast here . A webcast replay will be available for a limited time at the same address. To access the Company’s first quarter 2026 earnings slides click here . Ionis’ Marketed Medicines   INDICATION for TRYNGOLZA ®   (olezarsen)   TRYNGOLZA ®   (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).   IMPORTANT SAFETY INFORMATION   CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.   WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticari